Phanes Therapeutics
Clinical trials sponsored by Phanes Therapeutics, explained in plain language.
-
New drug combo trial offers hope for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PT886 (Spevatamig) in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of PT886 alone, then testing it combined with chemothe…
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug targets tough-to-treat neuroendocrine cancers in early trial
Disease control Recruiting nowThis study tests a new drug, Peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The goal is to find safe doses and see if the drug works alone or with chemotherapy. About 203 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC